Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Millions more Americans might get access to GLP-1 drugs
Related: Crazy-expensive weight loss drugs may soon see a major change In other news, The Biden Administration is set to introduce a change that could impact more than 7 million people covered by Medicare and Medicaid.
GLP-1 weight-loss drugs might help protect kidneys
The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm. In the largest study to date on the effects of the drugs on the kidneys, researchers found GLP-1s help the protect the organs in people with or without diabetes.
Biden will move to have Medicare, Medicaid cover GLP-1 weight-loss meds
The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and Medicaid.
Medicare coverage of weight-loss drugs would drive up costs by billions of dollars
President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Ozempic and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.
Biden wants Medicare, Medicaid to cover pricey weight loss drugs such as Wegovy
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
Biden Proposes Medicare and Medicaid Cover Costly Weight-Loss Drugs for Millions of Obese Americans
Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid under a new rule the Biden administration proposed Tuesday morni
Biden proposes expanded coverage for weight loss drugs under Medicare, Medicaid
The Biden administration has proposed a plan for Medicare and Medicaid to offer coverage for weight loss medications, such as Ozempic and Wegovy.
Biden proposes requiring Medicare and Medicaid to cover weight loss drugs
Under a new proposal from President Biden, weight loss drugs would be covered by Medicare and Medicaid. NBC News medical contributor Dr. Natalie Azar joins José Díaz-Balart to provide insight on who would benefit from the expanded coverage and what the approval process would look like.
Biden Proposes Expanded Medicare, Medicaid Coverage of Obesity Drugs
Current rules for the Medicare and Medicaid government health insurance programs cover the use of drugs such as Mounjaro, Ozempic and Wegovy for certain conditions like diabetes, but not for obesity as a condition on its own.
Biden admin proposes obesity drugs covered by Medicare, Medicaid, NYTimes says
The Biden administration will propose that Medicare and Medicaid cover obesity medications, a proposal that would extend the access of the
5h
on MSN
Biden administration plans to expand coverage of GLP-1 drugs for Americans with Medicare & Medicaid
CNBC's Bertha Coombs joins 'Squawk on the Street' to report on Biden's administration plan to expand coverage of GLP-1 drugs ...
Yahoo
8h
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs
Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, ...
20h
on MSN
West Virginia residents struggle to afford GLP-1 weight loss drugs after state ends subsidy program
In 2020, West Virginia launched a pilot program to subsidize GLP-1 drugs for public employees, but the program was shuttered ...
11h
5 GLP-1 marketing trends as brands jump on weight loss drug craze
As use of GLP-1 weight loss drugs including Wegovy and Ozempic increases, brands are introducing new offerings.
MedPage Today
21h
Are GLP-1 Drugs Putting an End to Bariatric Surgery?
We go into depth, covering what bariatric surgery is, who needs it, why insurance makes it so hard to get it, and, most ...
1d
on MSN
As many as 1 in 5 people won't lose weight with GLP-1 drugs, experts say
About 20% of patients — as many as 1 in 5 — may not respond well to medications like Mounjaro and Wegovy, according to ...
STAT
21h
Inside the telehealth-fueled GLP-1 alternative market
The new class of
GLP-1
weight loss drugs have been blockbusters since they arrived on the market a few years ago. These ...
BioSpace
5h
Legal Challenge Over Lilly’s GLP-1 Shortages Highlights FDA’s Post-Chevron Vulnerability
Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...
7d
This new supplement aims to support natural GLP-1 production and gut health
Inno Supps’ Trim Biome™ GLP-1 is designed to support the body’s natural production of GLP-1 through a unique blend of ...
1d
on MSN
New supplement designed specifically to battle ‘Ozempic face’ and other GLP-1 side effects
Losing face? Take heart. A new supplement promises to put an end to the emaciated aesthetic of ‘Ozempic face.’ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Biden
Ozempic
Food and Drug Administration
Glucagon-like peptide-1
West Virginia
Feedback